• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Seattle Children's Research Institute, Kineta partner for autoimmune research

Seattle Children's Research Institute, Kineta partner for autoimmune research

June 12, 2014
CenterWatch Staff

Seattle Children's Research Institute and Kineta, a Seattle, Wash.-based privately held biotechnology company, have launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases such as multiple sclerosis, type 1 diabetes and rheumatoid arthritis.

"Funding for pediatric research lags disproportionately behind research funding for adult diseases. Thirty percent of the U.S. population is under the age of 21, and yet only 6% of the entire NIH's budget is devoted to pediatric medicine and care," said Jim Hendricks, Ph.D., president of Seattle Children's Research Institute. "This gap results in limited development of new therapies for children, who now often have no other choice than to use adult-only tested medications."

There are significant barriers in developing pediatric therapies and the lack of pediatric medication use information poses risks to children and teens. The shortage of appropriate formulations may deny access and expose them to medications that were not designed for their growing bodies. The challenge of recruiting sufficient numbers of pediatric patients for clinical research also delays the development of better therapies for pediatric diseases and conditions.

In 2013, the FDA approved 27 new drugs; just seven new drugs were approved for pediatric use that same year. And of the 55,000 clinical trials conducted between 2005 and 2010, only nine percent were designed for children.

ACT will rely on a collaborative funding model that combines philanthropic gifts made to Seattle Children's Research Institute with equity investments made to Kineta.

"For too long pediatric studies have been the neglected component of clinical trials," said Charles Magness, Ph.D., Kineta president and CEO. "Kineta has a drug candidate that has completed two adult clinical trials and is well positioned for a clinical trial, which could make a real advancement for autoimmune diseases in children."

For their first collaborative project, researchers from Kineta and Seattle Children's Research Institute have begun conducting preclinical laboratory tests to advance Kineta's lead compound, called ShK-186, as a potential treatment for lupus nephritis, an autoimmune disease that causes kidney inflammation. While medications currerntly available for lupus nephritis reduce the disease's resulting inflammation, they also suppress the immune system, a side effect particularly concerning in children. Early preclinical research studies have indicated that ShK-186, which is derived from sea anemone venom, reduces inflammation while leaving the immune system intact.

Initial funding will help move ACT's lupus nephritis research into a clinical setting. It also will support work to adapt ShK-186 to become a viable treatment for other autoimmune diseases.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing